D07001 + capecitabine + TS-1

This drug is a combination of three distinct oral chemotherapeutic agents: **D07001** (an absorption-enhanced oral formulation of gemcitabine using self-microemulsifying technology), **capecitabine** (an oral prodrug of 5-fluorouracil used widely in gastrointestinal and breast cancers), and **TS-1/S-1** (an oral fluoropyrimidine combining tegafur, gimeracil, and oteracil to provide sustained 5-fluorouracil release while reducing gastrointestinal toxicity). - **D07001** acts as an oral bioavailable gemcitabine, a nucleoside analog inhibiting DNA synthesis in cancer cells[1][3][5][7]. - **Capecitabine** is a 5-fluorouracil prodrug that interferes with DNA synthesis[6]. - **TS-1** leverages tegafur (prodrug of 5-FU), gimeracil (DPD inhibitor to increase 5-FU plasma levels), and oteracil (reduces gastrointestinal side effects) for anti-tumor effects[2][4][6]. This combination aims to provide multifaceted inhibition of DNA synthesis and cell replication, potentially with complementary safety and efficacy profiles.

Brand names

Xeloda

Other names

S-1 for TS-1S1 for TS-1S 1 for TS-1oral gemcitabine (D07001)capecitabinetegafur/gimeracil/oteracil (TS-1 composition)